HomeProductsBioactive CompoundsProtein Kinase TargetsBTKEvobrutinib
Chemical structure of CAS 1415823-73-2

Evobrutinib

CAS No.1415823-73-2
MDL No.N/A
MFC25H27N5O2
MW429.50
InChI KeyQUIWHXQETADMGN-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1415823-73-2
Product NameEvobrutinib

Biological Targets

BTK

Associated Conditions

relapsing-remitting multiple sclerosis·multiple sclerosis·liver disease·kidney disease·systemic lupus erythematosus·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.

Journal of medicinal chemistry • Vol. 62, Issue 17 • 2019
PMID: 31368705DOI: 10.1021/acs.jmedchem.9b00794

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

The New England journal of medicine • Vol. 380, Issue 25 • 2019
PMID: 31075187DOI: 10.1056/NEJMoa1901981

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.

Journal of immunology (Baltimore, Md. : 1950) • Vol. 202, Issue 10 • 2019
PMID: 30988116PMC: PMC6500888DOI: 10.4049/jimmunol.1800583

Documentation

Similar Products